Germany Drug Cost-Benefit Proposal Departs From U.K., Other Approaches
Executive Summary
Advisors to the German government have sketched an approach for evaluating drug costs relative to benefits that could depart significantly from the practices of established institutions like the U.K.'s National Institute for Health and Clinical Excellence
You may also be interested in...
Biosimilars Create Class-wide Competition, German Experience Finds
Follow-on biologics may be able to achieve broader market penetration if they are not deemed to be interchangeable or substitutable for a single reference product, according to Novartis
Biosimilars Create Class-wide Competition, German Experience Finds
Follow-on biologics may be able to achieve broader market penetration if they are not deemed to be interchangeable or substitutable for a single reference product, according to Novartis
Sandoz Hones Biosimilars Strategy
Novartis generics unit pursues two different approaches for the human growth hormone Omnitrope and the epoetin alfa follow-on Binocrit.